Table 1.
The patient baseline characteristic.
| Variables | n (%) |
|---|---|
| Age (mean ± SD) (years) | 35.5 ± 3.5 |
| Race/ethnicity | |
| Non-Hispanic White | 1664 (61.2) |
| Non-Hispanic Black | 268 (9.8) |
| Hispanic (All Races) | 373 (13.7) |
| Other | 416 (15.3) |
| Grade | |
| Well differentiated | 640 (23.5) |
| Moderately differentiated | 1443 (53.0) |
| Poorly/undifferentiated | 578 (21.2) |
| Unknown | 60 (2.2) |
| Histology | |
| IDC or mixed with other types of carcinoma | 2425 (89.1) |
| ILC or mixed with other types of carcinoma | 112 (4.1) |
| Other | 184 (6.8) |
| Tumor stage | |
| T1 | 2083 (76.6) |
| T2 | 638 (23.4) |
| PR status | |
| Negative | 145 (5.3) |
| Positive | 2567 (94.3) |
| Unknown | 9 (0.3) |
| Surgical procedure | |
| BCS | 1257 (46.2) |
| Mastectomy | 1464 (53.8) |
| Radiotherapy | |
| No | 1611 (59.2) |
| Yes | 1110 (40.8) |
| Chemotherapy | |
| No | 1662 (61.1) |
| Yes | 1059 (38.9) |
| Traditional RS cutoffs | |
| Low-risk | 1293 (47.5) |
| Intermediate-risk | 1122 (41.2) |
| High-risk | 306 (11.2) |
| TAILORx RS cutoffs | |
| Low-risk | 352 (12.9) |
| Intermediate-risk | 1814 (66.7) |
| High-risk | 555 (20.4) |
Abbreviations: BCS, breast conserving surgery; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; PR, progesterone receptor; RS, recurrence score; SD, standard deviation; T, tumor; TAILORx, Trial Assigning Individualized Options for Treatment.